Tag: Joseph Eron

In a commentary published by Nature Medicine, Dr. Myron Cohen and Dr. Joe Eron, leaders of the UNC Institute for Global Health and Infectious Diseases, identify numerous medical advances originating from U.S. federally funded HIV research. They say the future of HIV research and the U.S.’s scientific leadership depends on...

The National Institutes of Health held a congressional briefing July 9 at the Dirksen Senate Office Building in Washington, DC. Dr. Myron Cohen, director of the Institute for Global Health and Infectious Diseases, and Dr. Joe Eron, chief of infectious diseases, kicked off the briefing session with an overview of HIV...

There’s a new tool to help prevent HIV in people who are at risk of contracting the virus, and health experts say it has the potential to change the trajectory of the global epidemic and may be especially beneficial for some older adults. In June, the U.S. Food and Drug...

Hospitalization causes among persons with HIV (PWH) have shifted to non-AIDS conditions, but the complete disease profile of hospitalized PWH has not been well described. To inform hospitalization and readmission prevention efforts, Thibaut Davy-Mendez, PhD, MSPH, Sonia Napravnik, PhD, and Joseph J. Eron, MD, examined non-AIDS disease prevalence among PWH hospitalized in 4...

As HIV care improves, people with Aids are now hospitalized more for non-AIDS conditions.  Despite this, the complete disease profile of hospitalized people with HIV has not been well described. To inform hospitalization and readmission prevention efforts, researchers with the institute examined non-AIDS disease prevalence among PWH hospitalized in 4...

The ACTG (Advancing Clinical Therapeutics Globally, formerly the AIDS Clinical Trials Group) Network celebrates the A5321 trial, and a successful ten-year milestone this month. Joe Eron, MD, Chief of Infectious Diseases, is the ACTG Chair and leader of the ACTG Executive Committee. “The A5321 has been ongoing for 10 years...

Investigators with the Institute for Global Health and Infectious Diseases (IGHID) participated in the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, California, March 9-12. Following are some highlights.   In a CROI preview, Joe Eron, MD, was interviewed for the “Going Anti-Viral” IAS-USA podcast, discussing the...

In an interview with Dr. Michael Saag for the “Going Anti-Viral Podcast” posted March 7, Dr. Joe Eron described his presentation for the Conference on Retroviruses and Opportunistic Infections CROI (2025). The two discuss the state of HIV cure research, recognizing why it has been difficult to develop a cure...

The ID Fellowship Program led by Christopher Sellers, MD, MPH, held a reception for six graduating fellows at the Siena Hotel in Chapel Hill, on the evening of June 18. Joined by Joe Eron, MD, chief of the division of infectious diseases, Myron Cohen, MD, director of the Institute for...

The Lancet ID has published a tribute to Ada Adimora and her life, describing her as a “tireless and compassionate champion for the global HIV community.”  Myron Cohen, MD, director of the Institute for Global Health and Infectious Diseases, and Joe Eron, MD, chief of the division of infectious diseases were...

HIV/AIDS has been around for approximately 40 years, but many researchers say the end is in sight. The question is, will it be in our lifetime or just around the corner? This is a spotlight on the HIV CURE Center, comprising approximately 55 researchers and students, featuring David Margolis, MD, the...

Dissertations build on multiple disciplinary perspectives with new contributions to global health knowledge and practice. Lauren Zalla’s project, guided by infectious disease professors Ada Adimora, MD, MPH, and Joe Eron, MD, is a good example. Bringing clinical expertise to Zalla’s dissertation committee, they helped her design a study that explored...

HIV virus eradication is a complex health challenge due to its long-lived persistence and how it hides in latently infected cells that escape the body’s immune system. Effective HIV treatments have decreased the likelihood of someone developing AIDS, while helping individuals live long and healthy lives without transmission to sexual...

This study led by the UNC Institute for Global Health & Infectious Diseases, will enroll 7,500 COVID-positive individuals to answer some of the biggest questions about COVID-19. Investigators explain the study in this video. Over two years into the COVID-19 pandemic and researchers still are looking to answer some of...

Infectious disease research at the UNC Institute for Global Health and Infectious Diseases (IGHID) attracts unique people driven to make big change in the world. As HIV/AIDS turned 40 in 2021, the world was immersed in a different pandemic, one that brought reminders of the tremendous change science made possible...

The 2022 HPTN Annual Meeting took place June 5-8 in Washington, D.C., bringing hundreds of worldwide researchers, collaborators, community representatives, and government health officials together to share updates and accomplishments and re-engage with each other as a community. HPTN Principal Investigators Myron Cohen, MD, director of the UNC Institute for...

HIV-related mortality has decreased since 1996 due to improved treatments and evolving care guidelines, but the extent to which persons entering HIV care have a higher risk for death over the following years, compared with peers in the general population, has been unclear. Joseph Eron, MD, the Herman and Louise...

The Infectious Diseases Society of America, the nation’s leading infectious diseases professional society, has elected the Institute’s Joseph Eron, MD; Anne Lachiewicz, MD, MPH; and Christopher Hurt, MD, to its latest cohort of Fellows of IDSA. As the highest honor in the field of infectious diseases, IDSA fellowships recognize those...

  The National Institutes of Health has awarded University of North Carolina’s Institute for Global Health & Infectious Diseases nearly $25 million over seven years to continue operating its Global HIV Clinical Trials Unit, or CTU. The new funding will support HIV treatment and prevention in adults, children and pregnant...

  Last week’s authorization by the U.S. Food and Drug Administration for emergency use of bamlanivimab feels like a shot in the arm, so to speak, for David Wohl, MD, a UNC infectious diseases physician and researcher. A monoclonal antibody developed by Eli Lilly to treat mild to moderate COVID-19,...